Skip to main content

Advertisement

Table 2 The relationship between m6A enzyme mRNA expression and clinicopathological parameters with clinical patients of breast cancer

From: Changes of N6-methyladenosine modulators promote breast cancer progression

Parameter Status (No.) METTL3 (mRNA) METTL14
(mRNA)
WTAP
(mRNA)
KIAA1429
(mRNA)
FTO
(mRNA)
ALKBH5
(mRNA)
Age ≤51 (16) 0.89 ± 0.54 0.80 ± 0.53 0.80 ± 0.44 2.14 ± 1.31 0.92 ± 1.71 1.59 ± 1.23
> 51 (20) 0.72 ± 0.50 0.81 ± 0.56 0.79 ± 0.36 1.85 ± 1.24 0.76 ± 0.46 1.78 ± 1.38
ER (IHC) - (13) 0.55 ± 0.18 0.53 ± 0.30 0.81 ± 0.41 1.44 ± 1.39 0.59 ± 0.63 1.07 ± 0.50
+(23) 0.89 ± 0.59* 0.93 ± 0.59* 0.78 ± 0.38 2.21 ± 1.12 0.92 ± 0.49* 2.02 ± 1.48*
PR (IHC) -(15) 0.59 ± 0.23 0.65 ± 0.36 0.78 ± 0.44 1.33 ± 0.90 0.63 ± 0.46 1.08 ± 0.23
+(21) 0.95 ± 0.63* 0.96 ± 0.64* 0.81 ± 0.35 2.33 ± 1.07* 1.01 ± 0.58* 2.20 ± 1.52*
HER2 (IHC) -(14) 0.72 ± 0.38 0.81 ± 0.45 0.77 ± 0.36 2.46 ± 1.32 0.74 ± 0.41 1.48 ± 0.71
+(22) 0.81 ± 0.58 0.81 ± 0.59 0.80 ± 0.40 1.67 ± 1.11 0.86 ± 0.62 1.83 ± 1.55
TNBC +(4) 0.31 ± 0.07 0.30 ± 0.21 0.60 ± 0.09 0.89 ± 0.36 0.41 ± 0.33 1.13 ± 0.68
-(32) 0.83 ± 0.51* 0.96 ± 0.54 0.81 ± 0.40 2.08 ± 1.26 0.86 ± 0.56 1.77 ± 1.36
  1. ER estrogen receptor, PR progesterone-receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer. *p < 0.05